Shares of Intellia Therapeutics surged 13.5% to $14.77 after a Zacks research note flagged the CRISPR gene-editing firm as statistically likely to beat Wall Street's earnings estimates ahead of its next report. The rally comes at a pivotal moment: Intellia is burning cash fast, just diluted shareholders with a massive stock sale, and is racing to bring the world's first in-body gene-editing drug to market.
Four Straight Earnings Beats Give the Signal Teeth. Zacks concluded that Intellia "will most likely beat the consensus EPS estimate." That's not idle speculation. In Q1 2026, Intellia reported a loss of $0.81 per share versus the expected $0.92, compared to a $1.10 loss a year ago.
Over the last four quarters, the company has beaten consensus EPS estimates four times. For a company that generates no product revenue yet, a shrinking loss trajectory tells investors that cash is being managed more tightly — a critical signal when you're burning roughly $96 million per quarter.
A $195 Million Stock Sale Looms Over the Rally. In late April, Intellia completed an equity offering of over 19 million shares, raising approximately $194.6 million in net proceeds.
Shares were priced at $10.75 each — well below today's price, which means new buyers are already in the money. But the dilution is real. Combined with $517.2 million in existing cash, the raise extends Intellia's funding runway into at least 2028 — past a potential U.S. drug launch.
The Real Catalyst Is a Drug, Not an Earnings Number. Intellia's Phase 3 trial of its one-time gene-editing treatment for hereditary angioedema showed an 87% reduction in attacks versus placebo.
The company has begun a rolling application to the FDA for approval, plans to complete it in the second half of 2026, and targets a U.S. launch in the first half of 2027. If approved, it would be the first in-body CRISPR therapy ever sold commercially.
Wall Street Is Deeply Split on What This Stock Is Worth. The average analyst price target sits at $26.47 — nearly 80% above today's price. Yet Goldman Sachs maintains a Sell rating with a $9 target. That gap reflects the core tension: Intellia is either a future pharmaceutical giant or a cash-burning bet that hasn't sold a single dose. Today's pop on an earnings-beat signal is encouraging, but the August report and mid-2026 clinical milestones will matter far more.